126 related articles for article (PubMed ID: 17970386)
1. Data briefing. The NICE threshold.
Appleby J
Health Serv J; 2007 Sep; 117(6074):21. PubMed ID: 17970386
[No Abstract] [Full Text] [Related]
2. Should NICE's threshold range for cost per QALY be raised? No.
Raftery J
BMJ; 2009 Jan; 338():b185. PubMed ID: 19171562
[No Abstract] [Full Text] [Related]
3. Should NICE's threshold range for cost per QALY be raised? Yes.
Towse A
BMJ; 2009 Jan; 338():b181. PubMed ID: 19171561
[No Abstract] [Full Text] [Related]
4. How NICE may be outflanked.
Ferner RE; McDowell SE
BMJ; 2006 May; 332(7552):1268-71. PubMed ID: 16735342
[No Abstract] [Full Text] [Related]
5. Saying no isn't NICE - the travails of Britain's National Institute for Health and Clinical Excellence.
Steinbrook R
N Engl J Med; 2008 Nov; 359(19):1977-81. PubMed ID: 18987366
[No Abstract] [Full Text] [Related]
6. Reflections: NICE, health economics, and outcomes research.
Rawlins M
Value Health; 2012 May; 15(3):568-9. PubMed ID: 22583468
[No Abstract] [Full Text] [Related]
7. NICE public health guidance: what's new?
Killoran A; White P; Owen L; Fischer A; Millward L
J Public Health (Oxf); 2009 Mar; 31(1):184-6. PubMed ID: 19153093
[No Abstract] [Full Text] [Related]
8. Value based pricing for NHS medicines: magic bullet, counterfeit treatment or the mixture as before?
Taylor D; Craig T
Health Econ Policy Law; 2009 Oct; 4(Pt 4):515-26. PubMed ID: 19715634
[No Abstract] [Full Text] [Related]
9. Can NICE be nicer? In a world of budget constraints there are no easy solutions.
Drummond M; Sorenson C
Value Health; 2009; 12(5):634-6. PubMed ID: 19402855
[TBL] [Abstract][Full Text] [Related]
10. The appropriate role of cost-effectiveness in determining device coverage: a case study of drug-eluting stents.
Firth BG; Cooper LM; Fearn S
Health Aff (Millwood); 2008; 27(6):1577-86. PubMed ID: 18997214
[TBL] [Abstract][Full Text] [Related]
11. Victory for NICE as High Court rejects drugs firm complaints.
Evans O
Health Serv J; 2007 Aug; 117(6069):5. PubMed ID: 17847890
[No Abstract] [Full Text] [Related]
12. Data briefing. Why NICE values some lives more.
Appleby J
Health Serv J; 2009 Feb; 119(6142):19. PubMed ID: 19326515
[No Abstract] [Full Text] [Related]
13. Value-based pricing of drugs in the UK.
Webb DJ; Walker A
Lancet; 2007 Apr; 369(9571):1415-1416. PubMed ID: 17467498
[No Abstract] [Full Text] [Related]
14. Validation--how much can the world afford? Are we getting value for money?
Anisfeld MH
J Pharm Sci Technol; 1994; 48(1):45-8. PubMed ID: 8004419
[TBL] [Abstract][Full Text] [Related]
15. Government pushes ahead with plan for cheaper drugs deal for NHS.
Timmins N
BMJ; 2007 Aug; 335(7614):273. PubMed ID: 17690350
[No Abstract] [Full Text] [Related]
16. NICE work: nice try.
Shuster S
BMJ; 2006 Jun; 332(7554):1394. PubMed ID: 16763270
[No Abstract] [Full Text] [Related]
17. Raising the standards of trial-based economic evaluation: the devil is in the detail.
Backhouse ME
Value Health; 2005; 8(5):519-20. PubMed ID: 16176490
[No Abstract] [Full Text] [Related]
18. NICE uses wrong comparator to assess cost effectiveness of new drugs, report says.
Hawkes N
BMJ; 2014 Mar; 348():g2134. PubMed ID: 24647344
[No Abstract] [Full Text] [Related]
19. Cost-effectiveness considerations at NICE.
Rawlins M; Dillon A
Lancet; 2008 Oct; 372(9646):1302. PubMed ID: 18929903
[No Abstract] [Full Text] [Related]
20. Sir Michael Rawlins on being NICE--and fair--about drug development and availability. Interview by Daniel Clarke.
Rawlins SM
Drug Discov Today; 2005 Mar; 10(6):383-6. PubMed ID: 15808816
[No Abstract] [Full Text] [Related]
[Next] [New Search]
